NEW YORK (Reuters Health) Jul 05 –
Treatment with the endothelin-A receptor antagonist sitaxsentan appears to improve the exercise capacity and cardiopulmonary hemodynamics of patients with pulmonary arterial hypertension (PAH), according to a report in the June issue of Chest.
Despite these encouraging finding, the drug may have serious adverse hepatic effects and further studies are needed.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!